Published in J Alzheimers Dis Parkinsonism on April 01, 2014
Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. Front Neurol (2015) 0.81
PET Imaging of Epigenetic Influences on Alzheimer's Disease. Int J Alzheimers Dis (2015) 0.78
Insight into the Molecular Imaging of Alzheimer's Disease. Int J Biomed Imaging (2016) 0.75
The Potential of Metabolic Imaging. Semin Nucl Med (2016) 0.75
Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features. J Alzheimers Dis (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Measurement of functional activities in older adults in the community. J Gerontol (1982) 10.07
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Clinical practice. Mild cognitive impairment. N Engl J Med (2011) 4.16
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol (2003) 3.47
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis (2013) 3.10
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci (2009) 2.32
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc (1981) 2.05
Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage (2010) 2.04
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr (1983) 1.77
The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol B Psychol Sci Soc Sci (1996) 1.73
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med (2011) 1.67
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med (2013) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis (2012) 1.56
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain (2010) 1.44
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci (2005) 1.38
Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis (2014) 1.36
Brain amyloid imaging. J Nucl Med (2011) 1.35
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain (2013) 1.31
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys (2010) 1.28
Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med (2012) 1.22
Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry (2011) 1.22
Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging (1997) 1.20
Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med (2001) 1.16
Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging (2008) 1.15
Metabolic brain covariant networks as revealed by FDG-PET with reference to resting-state fMRI networks. Brain Connect (2012) 1.11
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging (2012) 1.10
Quantitative assessment of the density of neurofibrillary tangles and senile plaques in senile dementia of the Alzheimer type. Comparison of immunocytochemistry with a specific antibody and Bodian's protargol method. Acta Neuropathol (1987) 1.10
Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging (2010) 1.10
Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. Hum Brain Mapp (2000) 1.09
Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging (2009) 1.08
Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol (1989) 1.04
Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med (2013) 1.00
Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology (2009) 0.99
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther (2013) 0.99
Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry (2010) 0.97
Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging (2007) 0.96
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry (2003) 0.96
Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med (2013) 0.95
Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med (2013) 0.92
Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses. Neuroimage (2012) 0.92
Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage (2013) 0.90
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.84
Computer-assisted system for diagnosis of Alzheimer disease using data base- independent estimation and fluorodeoxyglucose- positron-emission tomography and 3D-stereotactic surface projection. AJNR Am J Neuroradiol (2011) 0.78